Glenmark gets USFDA nod for generic asthma drug
Date: 15-07-2010Glenmark has received the approval of
The market for theophylline tablets is estimated to be USD 8 million per annum and GGI expects a successful launch, based on limited competition existing in this niche segment. Theophylline extended-release tablets are indicated for treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases such as emphysema and chronic bronchitis. crackcrack